<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Besides, the clinical trials of a combination of two anti-HIV drugs—lopinavir and ritonavir—have also been started for these drugs against the SARS-CoV-2 pathology [
 <xref ref-type="bibr" rid="CR59">59</xref>]. These drugs are used in a fixed-dose combination for the treatment and prevention of HIV/AIDS [
 <xref ref-type="bibr" rid="CR60">60</xref>]. A recent study reported that the β-coronavirus viral loads of a COVID-19 patient in Korea were significantly reduced after lopinavir/ritonavir treatment [
 <xref ref-type="bibr" rid="CR61">61</xref>]. In contrast, another clinical trial on hospitalized adult patients with severe COVID-19 shows no benefit with the lopinavir-ritonavir treatment [
 <xref ref-type="bibr" rid="CR62">62</xref>].
</p>
